ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Fusobacterium nucleatum, inflammation, and immunity: the fire within human gut.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it, 130 citations in OpenAlex.
- Perturbations in gut microbiota in autism spectrum disorder: a systematic review.Frontiers in neuroscience · 2025Pooled it
- Gut microbiome changes due to sleep disruption in older and younger individuals: a case for sarcopenia?Sleep · 2022Pooled it
- Trial
- Curcumin blocks Fusobacterium nucleatum-driven tumor progression and carcinogenesis in ESCC via inhibiting the TLR4/MYD88/TRIF/STAT3 axis.Journal of gastroenterology · 2026Article
- Fusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression.Clinical and translational medicine · 2026Review
- Abdominal Pain After Bariatric Surgery and the Role of the Gut: A Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Review
- Targeting Intratumoral Bacteria for Enhanced Tumor Suppression with Nano-Based Therapeutics: A Scoping Review.Pharmaceutics · 2026Review
- The multifaceted role of oral microbiota-host interactions in oral submucous fibrosis: from pathogenic mechanisms to microecological regulation therapies.Frontiers in microbiology · 2026Review
- Review
- Fat taste sensitivity in women with obesity: transcriptomic analysis of fungiform papillae before and after bariatric surgery.Obesity (Silver Spring, Md.) · 2025Article
- The Role of Gut Microbiota in Gastrointestinal Immune Homeostasis and Inflammation: Implications for Inflammatory Bowel Disease.Biomedicines · 2025Review
- Biochemical insight into gut microbial imbalance in Covid-19 and post vaccination heart attacks.World journal of microbiology & biotechnology · 2025Article
- Modulating Gut Microbiota with Dietary Components: A Novel Strategy for Cancer-Depression Comorbidity Management.Nutrients · 2025Review
- Role of gut microbiota and mesenteric adipose tissue in the pathology of Crohn's disease: Potential therapeutic targets.World journal of gastroenterology · 2025Article
- Expanding the human gut microbiome atlas of Africa.Nature · 2025Article
- A Novel Bacteriophage with the Potential to InhibitAntibiotics (Basel, Switzerland) · 2025Article
- Oral microbiota in aging and diseases.Life medicine · 2024Review
- Friend or Foe: Exploring the Relationship between the Gut Microbiota and the Pathogenesis and Treatment of Digestive Cancers.Microorganisms · 2024Review
- The oral-gut microbiome axis in inflammatory bowel disease: from inside to insight.Frontiers in immunology · 2024Review
- Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease.Intestinal research · 2024Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fusobacterium nucleatum is an identified proinflammatory autochthonous bacterium implicated in human colorectal cancer. It is also abundantly found in patients suffering from chronic gut inflammation (inflammatory bowel disease), consequently contributing to the pathogenesis of colorectal cancer. Majority of the studies have reported that colorectal tumors/colorectal adenocarcinomas are highly enriched with F. nucleatum compared to noninvolved adjacent colonic tissue. During the course of multistep development of colorectal cancer, tumors have evolved many mechanisms to resist the antitumor immune response. One of such favorite ploy is providing access to pathogenic bacteria, especially F. nucleatum in the colorectal tumor microenvironment, wherein both (colorectal tumors and F. nucleatum) exert profound effect on each other, consequently attracting tumor-permissive myeloid-derived suppressor cells, suppressing cytotoxic CD8+ T cells and inhibiting NK cell-mediated cancer cell killing. In this review, we have primarily focused on how this bug modulates the immune response, consequently rendering the antitumor immune cells inactive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.